Microarray data of transcriptome shifts in blood cell subsets during S1P receptor modulator therapy
Open Access
- 24 July 2018
- journal article
- research article
- Published by Springer Nature in Scientific Data
- Vol. 5 (1) , 180145
Abstract
Treatment with fingolimod, a sphingosine-1-phosphate (S1P) receptor modulator, prevents the egress of immune cell subpopulations from lymphoid tissues into the blood. We obtained peripheral blood samples from patients with relapsing multiple sclerosis before the initiation of fingolimod therapy, after one day and after 3 months. To investigate the differential expression induced by the drug, five different cell populations were isolated. We then employed 150 Human Transcriptome Arrays (HTA 2.0) interrogating >245,000 protein-coding and >40,000 non-coding transcript isoforms. After 3 months of treatment, CD4+ and CD8+ T-cells showed huge transcriptome shifts, whereas the profiles of B-cells (CD19+) were slightly altered and those of monocytes (CD14+) and natural killer cells (CD56+) remained unaffected. With >6 million probes for exons and splice junctions, our large HTA 2.0 dataset provides a deep view into alternative splicing patterns in immune cell subsets. Our data may also be useful for comparing the effects on gene expression signatures of novel S1P receptor modulators, which are currently tested in clinical trials for other autoimmune and neurodegenerative diseases.Keywords
This publication has 23 references indexed in Scilit:
- Multiple SclerosisNew England Journal of Medicine, 2018
- Disease modifying therapies for relapsing multiple sclerosisBMJ, 2016
- Fingolimod therapy modulates circulating B cell composition, increases B regulatory subsets and production of IL-10 and TGFβ in patients with Multiple SclerosisJournal of Autoimmunity, 2016
- Immunopathology of multiple sclerosisNature Reviews Immunology, 2015
- Fingolimod Increases CD39-Expressing Regulatory T Cells in Multiple Sclerosis PatientsPLOS ONE, 2014
- Defining the clinical course of multiple sclerosisNeurology, 2014
- Reduction of the Peripheral Blood CD56bright NK Lymphocyte Subset in FTY720-Treated Multiple Sclerosis PatientsThe Journal of Immunology, 2011
- The outs and the ins of sphingosine-1-phosphate in immunityNature Reviews Immunology, 2011
- Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosisAnnals of Neurology, 2011
- Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple SclerosisNew England Journal of Medicine, 2010